Clinical Trial

Chidamide in Patients With Recurrent and Refractory Diffuse Large b

Unknown
View on ClinicalTrials.gov →
Record status
This record was last updated January 19, 2023 (before its estimated August 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
A Multicenter, Prospective, Observational Clinical Protocol for Chidamide in Combination With Rituximab and Lenalidomide (cR2) in Real-world Practice in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Protocol Amendment History 1 change
critical Trial status changed: Enrolling by Invitation → Unknown 2026-08-09
Trial Details
NCT Number NCT05690191
Lead Sponsor Second Affiliated Hospital of Soochow University
Conditions Diffuse Large B-cell Lymphoma
Enrollment 169 participants
Start Date 2021-06-01
Primary Completion 2026-08-01 (estimated)
Study Completion 2026-08-01 (estimated)
Updated on ClinicalTrials.gov 2023-01-19